

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Fosravuconazole L-lysine ethanolate

August 27, 2024

### **Therapeutic category**

Other chemotherapeutics

### **Non-proprietary name**

Fosravuconazole L-lysine ethanolate

### **Safety measure**

PRECAUTIONS should be revised.

Revised language is underlined.

Current			Revision		
10.INTERACTIONS			10. INTERACTIONS		
10.2 Precautions for Co-Administration (This drug should be administered with caution when co-administered with the following.)			10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)		
Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors	Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
Drugs metabolized mainly by CYP3A Simvastatin Midazolam etc.	Fosravuconazole L-lysine ethanolate may increase the blood concentration of these drugs.	The metabolism of these drugs is suppressed by the inhibitory activities of ravuconazole against CYP3A.	Drugs metabolized mainly by CYP3A Simvastatin Midazolam <u>Azelnidipine</u> etc.	Fosravuconazole L-lysine ethanolate may increase the blood concentration of these drugs.	The metabolism of these drugs is suppressed by the inhibitory activities of ravuconazole against CYP3A.